Your browser doesn't support javascript.
loading
Multifocality and multicentricity in breast cancer and survival outcomes.
Lynch, S P; Lei, X; Chavez-MacGregor, M; Hsu, L; Meric-Bernstam, F; Buchholz, T A; Zhang, A; Hortobagyi, G N; Valero, V; Gonzalez-Angulo, A M.
Affiliation
  • Lynch SP; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Lei X; Departments of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Chavez-MacGregor M; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Hsu L; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Meric-Bernstam F; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Buchholz TA; Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Zhang A; Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Hortobagyi GN; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Valero V; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Gonzalez-Angulo AM; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: agonzalez@mdanderson.org.
Ann Oncol ; 23(12): 3063-3069, 2012 Dec.
Article in En | MEDLINE | ID: mdl-22776706
ABSTRACT

BACKGROUND:

The clinicopathological characteristics and the prognostic significance of multifocal (MF) and multicentric (MC) breast cancers are not well established. PATIENTS AND

METHODS:

MF and MC were defined as more than one lesion in the same quadrant or in separate quadrants, respectively. The Kaplan-Meier product limit was used to calculate recurrence-free survival (RFS), breast cancer-specific survival (BCSS), and overall survival (OS). Cox proportional hazards models were fit to determine independent associations of MF/MC disease with survival outcomes.

RESULTS:

Of 3924 patients, 942 (24%) had MF (n = 695) or MC (n = 247) disease. MF/MC disease was associated with higher T stages (T2 26% versus 21.6%; T3 7.4% versus 2.3%, P < 0.001), grade 3 disease (44% versus 38.2%, P < 0.001), lymphovascular invasion (26.2% versus 19.3%, P < 0.001), and lymph node metastases (43.1% versus 27.3%, P < 0.001). MC, but not MF, breast cancers were associated with a worse 5-year RFS (90% versus 95%, P = 0.02) and BCSS (95% versus 97%, P = 0.01). Multivariate analysis shows that MF or MC did not have an independent impact on RFS, BCSS, or OS.

CONCLUSIONS:

MF/MC breast cancers were associated with poor prognostic factors, but were not independent predictors of worse survival outcomes. Our findings support the current TNM staging system of using the diameter of the largest lesion to assign T stage.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Lymphatic Metastasis / Neoplasm Metastasis Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2012 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Lymphatic Metastasis / Neoplasm Metastasis Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2012 Type: Article Affiliation country: United States